New hope for bile duct cancer: experimental drug enters final testing phase
NCT ID NCT07265674
First seen Dec 10, 2025 · Last updated May 03, 2026 · Updated 17 times
Summary
This study tests a new drug called nanvuranlat in people with advanced biliary tract cancer (bile duct cancer) that has already been treated. About 480 adults will receive either nanvuranlat or standard treatments (chemotherapy or supportive care). The goal is to see if nanvuranlat helps people live longer and slows cancer growth. Treatment continues as long as it works and side effects are manageable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Allegheny Health Network (Site 121)
NOT_YET_RECRUITINGPittsburgh, Pennsylvania, 15212, United States
-
Banner MD Anderson Cancer Center (Site 106)
NOT_YET_RECRUITINGGilbert, Arizona, 85234, United States
-
City of Hope (Site 107)
NOT_YET_RECRUITINGDuarte, California, 91010, United States
-
Henry Ford Cancer Center (Site 113)
NOT_YET_RECRUITINGDetroit, Michigan, 48186, United States
-
James Cancer Hospital and Solove Research Institute (Site 119)
NOT_YET_RECRUITINGColumbus, Ohio, 43219, United States
-
Karmanos Cancer Center (Site 109)
NOT_YET_RECRUITINGDetroit, Michigan, 48201, United States
-
Masonic Cancer Center, University of Minnesota (Site 116)
NOT_YET_RECRUITINGMinneapolis, Minnesota, 55455, United States
-
Memorial Sloan Kettering Cancer Center (Site 108)
NOT_YET_RECRUITINGNew York, New York, 10065, United States
-
Mercy Clinic (Site 110)
RECRUITINGOklahoma City, Oklahoma, 73120, United States
-
Norton Cancer Institute (Site 115)
NOT_YET_RECRUITINGLouisville, Kentucky, 40127, United States
-
Ochsner Medical Center (Site 120)
NOT_YET_RECRUITINGNew Orleans, Louisiana, 70121, United States
-
Rosewell Park Comprehensive Cancer Center (Site 114)
NOT_YET_RECRUITINGBuffalo, New York, 14263, United States
-
Rutgers Cancer Institute of New Jersey (Site 103)
RECRUITINGNew Brunswick, New Jersey, 08901, United States
-
UCLA Medical Center (Site 117)
NOT_YET_RECRUITINGSanta Monica, California, 90404, United States
-
University Hospitals Cleveland Medical Center Seidman Cancer Center (Site 111)
RECRUITINGCleveland, Ohio, 44106, United States
-
University of California at Irvine (Site 101)
NOT_YET_RECRUITINGOrange, California, 92868, United States
-
University of Texas MD Anderson Cancer Center (Site 102)
NOT_YET_RECRUITINGHosuton, Texas, 77030, United States
-
University of Texas Southwestern Medical Center (Site 104)
NOT_YET_RECRUITINGDallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.